Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06132568 · ClinicalTrials.gov registry record · NA

VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)

A NA study of High-risk Percutaneous Coronary Intervention and Heart Disease, Coronary, sponsored by Boston Scientific Corporation.

Completed
Registry status
NA
Development phase
15
Enrollment target
5
Study locations

NCT06132568 is a NA study of High-risk Percutaneous Coronary Intervention and Heart Disease, Coronary that has completed, run by Boston Scientific Corporation. The registered enrollment target is 15 participants. The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06132568, a NA study of High-risk Percutaneous Coronary Intervention and Heart Disease, Coronary, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target
5
Study locations

Study Summary

The VITALYST Early Feasibility study (EFS) is designed to evaluate the feasibility and safety of the VITALYST System in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).

Interventions

  • DEVICE VITALYST System

Study Locations (5)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

Georgia

  • Piedmont Heart Institute - Atlanta

New York

  • Columbia University Medical Center/New York Presbyterian Hospital - New York

Other

  • Skane University Hospital - Lund

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2024-05-09
Est. Completion 2025-01-17
Phase NA

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT06132568

The ClinicalTrials.gov registry entry for NCT06132568 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with High-risk Percutaneous Coronary Intervention appearing as the primary indexed condition, and to 1 intervention - of which VITALYST System is the first listed.

NCT06132568 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Georgia, New York.

Frequently Asked Questions

What is clinical trial NCT06132568 about?

NCT06132568 is a clinical study titled "VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)". The VITALYST Early Feasibility study (EFS) is designed to evaluate the feasibility and safety of the VITALYST System in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).

What is the current status of trial NCT06132568?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2024-05-09. Estimated completion is 2025-01-17.

What conditions does trial NCT06132568 study?

This clinical trial studies the following conditions: High-risk Percutaneous Coronary Intervention, Heart Disease, Coronary.

What interventions are being tested in trial NCT06132568?

The interventions under investigation include: VITALYST System (DEVICE).

Who is sponsoring clinical trial NCT06132568?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06132568 being conducted?

This trial has 5 study locations across Georgia, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for High-risk Percutaneous Coronary Intervention

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.